BioVie Inc Dossier
Qualitative Analysis
Business overview
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing innovative drug therapies to treat chronic, debilitating conditions. The company's pipeline targets two primary therapeutic areas: neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease) and advanced liver disease. Its lead clinical asset is bezisterim (also known as NE3107), an orally administered, blood-brain barrier-permeable small molecule designed to target neuroinflammation and insulin resistance. Bezisterim works by selectively inhibiting inflammatory extracellular signal-regulated kinase (ERK1/2) signaling, thereby downregulating NF-κB-mediated inflammatory pathways and reducing the expression of pro-inflammatory cytokines such as TNF-α and IL-6. Additionally, the company has historically developed BIV201 (continuous infusion terlipressin) for complications of liver cirrhosis, such as refractory ascites, though recent strategic shifts have prioritized the CNS pipeline and explored spinout opportunities for its liver assets.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead candidate bezisterim (NE3107), an oral anti-inflammatory small molecule targeting neuroinflammation and insulin resistance, across Parkinson's disease, Alzheimer's disease, and Long COVID.
Expected impact: Establish clinical efficacy and secure regulatory approvals for disease-modifying therapies in major neurodegenerative and inflammatory markets.
Developing BIV201 (continuous infusion of terlipressin) for the treatment of refractory ascites and hepatorenal syndrome (HRS-AKI) associated with advanced liver cirrhosis.
Expected impact: Provides a nearer-term commercial catalyst with FDA Orphan Drug and Fast Track designations in an underserved orphan indication.
Disciplined management of operating expenses, particularly R&D and G&A, to extend the cash runway into early 2027 while advancing key clinical milestones.
Expected impact: Minimizes near-term shareholder dilution and maintains financial flexibility ahead of binary clinical readouts.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of NeurMedix's biopharmaceutical assets, including lead drug candidate NE3107 (now bezisterim), which pivoted BioVie's pipeline into neurodegenerative and neuroinflammatory diseases.
Financial impact: The transaction was primarily structured in stock and cash, establishing bezisterim as the core driver of BioVie's long-term valuation.
Strategic Partnerships
High; provides a $13.1 million non-dilutive grant to fully fund the Phase 2 ADDRESS-LC clinical trial for Long COVID.
Terms: $13.1 million non-dilutive award secured in April 2024.